It’s time to start thinking about seasonal vaccinations. Getting those annual jabs isn’t quite as simple as it was before the ...

Urge your representatives in Congress to support its programs to increase access to vaccines around the world.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that adults over 65 and immunocompromised people get ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Last week I saw a somewhat shabbily dressed man in the pharmacy trying to get a Covid booster. They told him it would cost $130. (It was the Moderna ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...

UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.

The CDC recommends that immunocompromised people age 65 and older should get a second dose of the 2024-2025 COVID vaccine.